Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the August 2011 issue of Nature Biotechnology titled “US Court Bolsters Biotech Patent Protection.” Brinckerhoff discusses the outcome of Therasense vs. Becton Dickinson & Company and its significance to biotech companies. She observes that the decision offers patent holders a new basis for defeating an inequitable conduct charge, but adds that litigants are likely to continue raising the defense in order to render an entire patent unenforceable until more court decisions have rejected weaker charges of inequitable conduct.
People
Related News
December 18, 2025
In the News
Kyle Faget Weighs in on HHS Proposed Rule Limiting Gender-Affirming Care
Foley & Lardner LLP partner Kyle Faget commented on a recent proposal from the U.S. Department of Health and Human Services in the Law360 article, “HHS Proposes Hospital Ban On Gender Care For Minors.”
December 12, 2025
In the News
Foley Chairman and CEO Daljit Doogal Talks Firm Strategy and Growth, Featured in Media for Reelection
Foley & Lardner LLP Chairman and CEO Daljit Doogal is featured in The American Lawyer article, “Foley Board Taps Daljit Doogal for Second Term as Chair and CEO,” for his reelection to a second four-year term.
December 11, 2025
In the News
Carrie Hoffman Comments on SCOTUS Arbitration Jurisdiction Case
Foley & Lardner LLP partner Carrie Hoffman commented on the U.S. Supreme Court's decision to hear an arbitration jurisdiction case in the Law360 article, "High Court Arb. Jurisdiction Case May Impact W&H Cases."